Therefore, we demonstrate that targeting IDO1 to reverse T cell dysfunction could be an effective strategy for enhancing the efficacy of immunotherapy in BRAF V600E-mutant CRC. The gene discussed is IDO1; the disease is colorectal carcinoma.